Cognition’s FDA Win: A New Front in the War on Lewy Body Dementia

PURCHASE, NY – June 24, 2026 – In a significant development for neurodegenerative disease treatment, Cognition Therapeutics announced it has received crucial positive feedback from the U.S. Food and Drug Administration (FDA). The agency has aligned with the company on key design aspects for a pivotal Phase 3 trial of its lead drug candidate, zervimesine (CT1812), aimed at treating psychosis in patients with dementia with Lewy bodies (DLB). This alignment not only paves the way for a registrational study planned for mid-2027 but, more importantly, establishes DLB psychosis as a potentially approvable indication—a landmark moment for a patient population with no approved therapies.

For the estimated 1.4 million Americans and their families grappling with DLB, this news represents a beacon of hope. The disease is often overshadowed by its more famous cousin, Alzheimer's, yet it is a uniquely cruel and complex neurodegenerative disorder. The onset of psychosis, which affects up to 80% of patients, marks a devastating turning point, characterized by vivid, often frightening, visual hallucinations and delusions that profoundly impact quality of life and place an immense burden on caregivers.

The Unseen Crisis of DLB Psychosis

Unlike Alzheimer's, which is primarily a disease of memory, DLB attacks a broader range of neurological functions, causing cognitive decline, motor symptoms similar to Parkinson's disease, and severe neuropsychiatric issues. The psychosis associated with DLB is frequently cited as the most challenging aspect of the disease, often precipitating the need for institutionalization.

Currently, clinicians have no good options. There are no FDA-approved drugs specifically for DLB or its associated psychosis. The standard of care involves the risky off-label use of antipsychotic medications. This is a perilous choice, as DLB patients exhibit extreme neuroleptic sensitivity; these drugs can paradoxically worsen motor function, accelerate cognitive decline, and in some cases, trigger severe, life-threatening reactions. In fact, most antipsychotics carry an FDA "black box warning" highlighting an increased risk of death in elderly patients with dementia-related psychosis. It is a desperate trade-off between managing debilitating symptoms and accepting potentially catastrophic risks.

“The only recourse for DLB patients experiencing psychosis is the off-label use of potentially dangerous antipsychotics,” stated Dr. Anthony O. Caggiano, Chief Medical Officer of Cognition, in the company's announcement. The lack of a safe, effective, and durable treatment has created a profound and urgent unmet medical need.

A Regulatory Breakthrough and Novel Mechanism

Cognition's announcement is more than just a corporate milestone; it's a significant regulatory de-risking event that could set a precedent for the entire field. The FDA’s agreement that DLB psychosis is an “approvable outcome” provides a clear regulatory target that has been absent for decades. This formal acknowledgment validates the clinical importance of treating these symptoms and may encourage further investment and research into this neglected area.

Zervimesine itself represents a novel strategic approach to treatment. It is a first-in-class, once-daily oral therapy designed to target the underlying disease pathology. The drug is a sigma-2 receptor modulator that works by displacing toxic protein oligomers—clumps of proteins like beta-amyloid and alpha-synuclein—from their binding sites on brain cells. This action is believed to protect synapses, restore normal cellular function, and ultimately slow the progression of the disease, rather than merely masking symptoms.

This mechanism showed considerable promise in the company's Phase 2 'SHIMMER' trial. A recent analysis of that data revealed that zervimesine slowed the progression of hallucinations and delusions by a remarkable 89% compared to placebo over six months. This strong efficacy signal forms the foundation for the upcoming pivotal study and gives credence to the drug's potential as a disease-modifying therapy.

Charting the Path Forward: A Pivotal Trial Design

The proposed Phase 3 study, expected to launch in mid-2027, is designed to provide the definitive evidence needed for a New Drug Application (NDA). The trial will enroll DLB patients experiencing hallucinations and delusions, randomizing them to receive either a 100 mg daily dose of zervimesine or a placebo for nine months. Notably, the trial will permit patients to continue stable background treatment with off-label antipsychotics, reflecting a real-world clinical setting.

A key element of the trial design is the use of the Neuropsychiatric Inventory (NPI) as the primary endpoint. While the NPI is a well-validated and widely used tool for assessing behavioral symptoms in dementia research, its designation as a primary endpoint for a registrational trial in this specific context is novel. Cognition will work closely with the FDA to finalize the analytical and statistical plan for the NPI, ensuring the data collected is robust and interpretable for regulatory review. This collaboration is critical and demonstrates a willingness from both the company and the agency to forge a new path for evaluating treatments in this complex disease.

The Strategic Landscape for Cognition

From a strategic perspective, this FDA alignment significantly enhances Cognition Therapeutics' position. The company, which has adeptly secured nearly $200 million in non-dilutive grant funding from the National Institutes of Health and related foundations, has a financial cushion that reduces immediate reliance on the often-volatile equity markets to fund its ambitious clinical programs. With a cash runway projected into the second quarter of 2027, it has a window to advance its pipeline.

While also developing zervimesine for early Alzheimer's disease in the ongoing Phase 2 'START' study, the company has clearly and strategically prioritized the DLB psychosis program. This focused approach aims to achieve a faster path to a potential first market approval, capitalizing on the clear unmet need and the promising Phase 2 data. A successful outcome in DLB would not only provide a transformative therapy for patients but also validate the drug's mechanism of action, creating significant value and bolstering the case for its application in other neurodegenerative diseases.

“Our ultimate goal is to provide patients and their families with a durable treatment option for DLB psychosis that actually slows the progression of hallucinations and delusions,” said Lisa Ricciardi, President and CEO of Cognition. As the company prepares for its pivotal trial, it carries the hopes of a community that has, as Ricciardi noted, “waited too long” for a breakthrough.